Form 4: Fennec Pharmaceuticals Director Rosty Raykov Sells 10,000 Shares

Sentiment:

SEC Form 4 Filing


Director Rosty Raykov of Fennec Pharmaceuticals sold 10,000 common shares on April 4, 2025, at a price of $5.25 per share, according to a Form 4 filing.

Summary

  • Rosty Raykov, a director of Fennec Pharmaceuticals, sold 10,000 common shares of the company on April 4, 2025.
  • The shares were sold at a price of $5.25 per share.
  • The transaction was executed under a pre-arranged 10b5-1 trading plan established on August 23, 2024.
  • Following the transaction, Raykov directly owns 61,156 common shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged plan and doesn't inherently indicate a positive or negative outlook.

Industry Context

Sales by insiders are a normal part of corporate activity. It is important to consider the context of the sale, such as whether it is part of a pre-planned trading program, and to compare it to the trading activity of other insiders.

Key Dates

DateDescription
August 23, 2024Date of 10b5-1 plan adoption
04/04/2025Date of transaction (share sale)

Keywords

Fennec Pharmaceuticals, Rosty Raykov, Form 4, Share Sale, 10b5-1 Plan, Director, FENC

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.